A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

We sought to compare all‐cause mortality of people living with HIV and accessing care in Canada and the UK.

B. Gazzard | C. Leen | B. Yip | M. Wainberg | D. Pillay | A. Winston | C. Sabin | A. Burchell | A. Phillips | F. Lampe | M. Youle | M. Johnson | C. Archibald | J. Weber | J. Ainsworth | M. Cotterchio | T. Antoniou | M. Loutfy | L. Szadkowski | S. Walmsley | M. Gompels | L. Campbell | F. Ibrahim | C. Orkin | F. Post | J. Anderson | M. Nelson | N. Perry | I. Williams | Claire L. Allen | A. Rachlis | S. Sanche | A. Schwenk | C. Liddy | A. Bayoumi | B. Nosyk | S. Johnston | M. Harris | A. Babiker | D. Chadwick | A. Lewszuk | J. Montaner | D. Dunn | D. Corsi | C. Tsoukas | C. Cooper | D. Churchill | F. Martin | P. Hay | M. Smieja | S. Mandalia | M. Hull | A. Wong | Colette Smith | M. Sachikonye | A. Palfreeman | C. Atkinson | P. Phillips | J. Walsh | M. Fisher | V. Delpech | H. Samji | A. Palmer | A. Cescon | V. Lima | S. Guillemi | R. Gilson | D. Asboe | A. Thornton | C. Wood | T. Hill | E. Youssef | Deborah Kelly | David M Moore | R. Masching | J. Zhu | N. Machouf | C. Goldsmith | P. Richard Harrigan | Sean R. Hosein | S. Patterson | B. Trottier | Ken Clement | Monique Doolittle-Romas | L. Edmiston | Brian Huskins | Jerry Lawless | Douglas Lee | Stephen Tattle | A. Zahirieh | S. Calvez | G. Colley | Jason Chia | L. Gilbert | N. Gataric | L. Light | David Mackie | C. Pexos | S. Shurgold | J. Younger | F. Ramzan | David M. Moore | C. Chaloner | A. Wilson | J. Hand | S. Kegg | S. Jose | S. Huntington | N. Brima | J. Raboud | S. Hutchinson | Chris Taylor | R. Hogg | R. Trevelion | S. Morris | M. Carder | E. Ding | R. Everett | M. Klein | SB Rourke | Alia Leslie | J. Wong | S. Allan | J. Pritchard | A. Tariq | A. Glabay | S. Tilbury | H. Korat | Z. Gleisner | R. Tsintas | N. Mackie | J. Lynch | C. de Souza | S. Munshi | Sheila Miller | Sue Allan | K. Memon | E. Cope | J. Gibson | P. Main | M. Dhillon | S. Russell-Sharpe | A. Harte | S. Clay | H. Spencer | Ron Jones | S. Cumming | D. Kelly | S. Rourke | S. Johnston | S. Russell‐Sharpe

[1]  A. Thornton.  Viral hepatitis and HIV co-infection in the UK Collaborative HIV cohort (UK CHIC) study , 2015 .

[2]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[3]  R. Salamon,et al.  A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. , 2015, The New England journal of medicine.

[4]  R. Hogg,et al.  Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada , 2015, BMC Infectious Diseases.

[5]  Jean-Guy Baril.  La thérapie antirétrovirale pour les adultes infectés par le VIH. Version résumée : guide pour les professionnels de la santé du Québec / comité de rédaction, Dr Jean-Guy Baril [et 11 autres] , 2015 .

[6]  A. Pozniak,et al.  Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points , 2014, Journal of the International AIDS Society.

[7]  J. Sterne,et al.  Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) , 2014, HIV medicine.

[9]  Jennifer F Hoy,et al.  Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[10]  James J. Goedert,et al.  Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada , 2013, PloS one.

[11]  J. Sterne,et al.  Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. , 2012, International journal of epidemiology.

[12]  R. Hogg,et al.  Disparities in the Burden of HIV/AIDS in Canada , 2012, PloS one.

[13]  C. Leen,et al.  7.0 Managing virological failure , 2012, HIV medicine.

[14]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.

[15]  N. Ford,et al.  Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.

[16]  Curtis Cooper,et al.  Cohort profile: the Canadian Observational Cohort collaboration. , 2011, International journal of epidemiology.

[17]  L. D. Saunders,et al.  All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use. , 2011, Canadian journal of public health = Revue canadienne de sante publique.

[18]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Covinsky,et al.  Towards a combined prognostic index for survival in HIV infection: the role of ‘non‐HIV’ biomarkers , 2010, HIV medicine.

[20]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[21]  S. Jaffar,et al.  Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda , 2009, BMC public health.

[22]  B. Thiers.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2009 .

[23]  Jeffrey N. Martin,et al.  Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. , 2008, JAMA.

[24]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[25]  C. Archibald,et al.  Estimates of HIV prevalence and incidence in Canada, 2005. , 2006, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[26]  P. Morlat,et al.  Number of deaths among HIV-infected adults in France in 2000, three-source capture–recapture estimation , 2006, Epidemiology and Infection.

[27]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[28]  A. Huitema,et al.  Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily , 2005, HIV medicine.

[29]  Kholoud Porter,et al.  The creation of a large UK‐based multicentre cohort of HIV‐infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study , 2004, HIV medicine.

[30]  O. Kirk,et al.  Modelling the 3‐year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti‐HIV Drugs (DAD) study , 2003, HIV medicine.

[31]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[32]  Bg Gazzard and.  British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. , 2005, HIV medicine.

[33]  M. Schechter,et al.  Impact of HIV Infection on Mortality in a Cohort of Injection Drug Users , 2001, Journal of acquired immune deficiency syndromes.

[34]  British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy , 2000 .

[35]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[36]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[37]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[38]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[39]  J. Bartlett,et al.  Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services. , 1998, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.